Enanta Pharmaceuticals, Inc. Common Stock ENTA
i
Market dataready · fetched 2026-11-11T14:12:22.738Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:00.196060422Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-11T14:03:55.648627+00:00
Enanta Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 9.50 | 125.3% | 17.9% | |||
| 25Δ | 10.04 | 122.6% | 13.9% | |||
| 30Δ | 23.22 | 494.5% | 117.4% | 10.35 | 124.7% | 12.7% |
| 35Δ | 16.26 | 344.3% | 54.7% | 10.66 | 126.9% | 11.5% |
| 40Δ | 14.62 | 302.7% | 40.7% | 10.97 | 129.0% | 10.3% |
| 45Δ | 13.91 | 279.5% | 35.2% | 11.29 | 131.1% | 9.2% |
| 50Δ | 13.20 | 256.3% | 29.7% | 11.60 | 133.2% | 8.0% |
| 55Δ | 12.50 | 233.2% | 24.2% | 11.91 | 135.4% | 6.8% |
| 60Δ | 11.79 | 210.0% | 18.7% | 12.22 | 137.5% | 5.7% |
| 65Δ | 11.08 | 186.8% | 13.2% | 12.56 | 139.2% | 4.5% |
| 70Δ | 10.37 | 163.7% | 7.6% | 13.06 | 138.2% | 3.8% |
| 75Δ | 13.56 | 137.1% | 3.0% | |||
| 80Δ | 14.06 | 136.0% | 2.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.50
- IV
- 125.3%
- B/E move
- 17.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.04
- IV
- 122.6%
- B/E move
- 13.9%
30Δ
- Pseudo strike
- 23.22
- IV
- 494.5%
- B/E move
- 117.4%
- Pseudo strike
- 10.35
- IV
- 124.7%
- B/E move
- 12.7%
35Δ
- Pseudo strike
- 16.26
- IV
- 344.3%
- B/E move
- 54.7%
- Pseudo strike
- 10.66
- IV
- 126.9%
- B/E move
- 11.5%
40Δ
- Pseudo strike
- 14.62
- IV
- 302.7%
- B/E move
- 40.7%
- Pseudo strike
- 10.97
- IV
- 129.0%
- B/E move
- 10.3%
45Δ
- Pseudo strike
- 13.91
- IV
- 279.5%
- B/E move
- 35.2%
- Pseudo strike
- 11.29
- IV
- 131.1%
- B/E move
- 9.2%
50Δ
- Pseudo strike
- 13.20
- IV
- 256.3%
- B/E move
- 29.7%
- Pseudo strike
- 11.60
- IV
- 133.2%
- B/E move
- 8.0%
55Δ
- Pseudo strike
- 12.50
- IV
- 233.2%
- B/E move
- 24.2%
- Pseudo strike
- 11.91
- IV
- 135.4%
- B/E move
- 6.8%
60Δ
- Pseudo strike
- 11.79
- IV
- 210.0%
- B/E move
- 18.7%
- Pseudo strike
- 12.22
- IV
- 137.5%
- B/E move
- 5.7%
65Δ
- Pseudo strike
- 11.08
- IV
- 186.8%
- B/E move
- 13.2%
- Pseudo strike
- 12.56
- IV
- 139.2%
- B/E move
- 4.5%
70Δ
- Pseudo strike
- 10.37
- IV
- 163.7%
- B/E move
- 7.6%
- Pseudo strike
- 13.06
- IV
- 138.2%
- B/E move
- 3.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.56
- IV
- 137.1%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.06
- IV
- 136.0%
- B/E move
- 2.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 93.29% | |
| 78.86% | |
| 74.82% | |
| 78.11% | |
| 84.24% | |
| 84.78% | |
| 85.35% | |
| 83.43% | |
| 76.91% | |
| 93.43% | |
| 112.41% | |
| 140.94% | |
| 82.16% | |
| 81.67% | |
| 78.70% | |
| 78.75% | |
| 87.60% | |
| 91.74% | |
| 91.04% | |
| 97.59% | |
| 92.90% | |
| 92.95% | |
| 103.37% | |
| 108.68% | |
| 112.81% | |
| 105.03% | |
| 135.25% | |
| 206.19% | |
| 99.65% | |
| 87.09% | |
| 95.98% | |
| 97.14% | |
| 95.03% | |
| 94.19% | |
| 98.25% | |
| 94.72% | |
| 92.46% | |
| 99.94% | |
| 108.43% |
Biotechnology
ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in…
More →EVMN
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in…
More →EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
More →EXEL
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The…
More →EYPT
Description unavailable
More →